Short-Read Human WGS · 10× / 20× / 30× · Illumina NovaSeq 6000 & X

Match the depth to the question.

Not every genome needs the same depth. 10× is a cost-efficient tier for copy-number and cohort genotyping studies; 20× balances cost and content for population programmes; 30× is the standard for rare-disease diagnosis, cancer predisposition and discovery-grade variant detection. Nucleome Informatics runs all three tiers on Illumina NovaSeq with a GATK best-practices and DeepVariant analysis pipeline.

3
coverage tiers: 10× · 20× · 30×
2×150 bp
paired-end reads, PCR-free libraries
GRCh38
GATK + DeepVariant pipeline
5
disease areas: rare · cardio · cancer · metabolic · NCD

Human Whole Genome Sequencing (short read)

Nucleome Informatics offers human whole genome resequencing on Illumina NovaSeq 6000 and NovaSeq X at three coverage tiers, with analysis matched to each tier's detection limits and to your disease area.

What every project includes

  • Raw reads (FASTQ, 2×150 bp) with full QC: yield, Q30, mean depth, coverage uniformity, duplication and insert size
  • Alignment (BWA-MEM2) to GRCh38, delivered as BAM or space-saving CRAM
  • SNV and indel calls (GATK HaplotypeCaller / DeepVariant), with VQSR filtering where cohort size supports it
  • CNV calling from read depth at all tiers; structural variant calling (Manta-class) at 20× and 30×
  • Annotation (VEP) with population frequencies from gnomAD and Indian datasets (IndiGenomes), and ACMG/AMP classification for clinical-tier projects
  • Cohort analyses: ancestry/PCA, relatedness, homozygosity mapping, and PRS where the cohort is powered for it
  • A written report with methods, software versions and detection limits for your tier
  • Optional Advanced Analysis Package (30×): repeat-expansion screening, SMN1/SMN2 copy-number calling and mitochondrial variant calling

Disease-area applications

  • Rare disease: trio or duo WGS at 30× with de novo detection, homozygosity mapping for consanguineous families, CNV/SV calling, and optional ACMG SF v3.3 secondary findings with consent.
  • Cardiovascular: cardiomyopathy and arrhythmia genes (e.g. LMNA, MYH7, TTN), familial hypercholesterolaemia (LDLR, APOB, PCSK9), aortopathy and channelopathy genes.
  • Cancer: germline predisposition (BRCA1/2, Lynch syndrome genes, TP53); tumour–normal somatic designs are scoped separately at higher depth.
  • Metabolic disorders: inborn errors of metabolism such as PKU (PAH), Wilson disease (ATP7B), lysosomal storage, urea-cycle and fatty-acid oxidation defects.
  • Non-communicable diseases: type 2 diabetes and MODY (GCK, HNF1A), obesity, chronic kidney disease, and polygenic risk research in cohorts.

Three tiers, at a glance

Choose the tier from the question you need answered. We run the detection-limit calculation with you before samples are committed.

TierApprox. data per genomeBest forNot recommended for
10×~30–35 GbGenome-wide CNV and aneuploidy profiling, cohort genotyping (with joint calling or imputation), ancestry and population structureDiagnostic SNV/indel calling; heterozygous variant sensitivity is reduced
20×~60–70 GbPopulation and cohort programmes, association studies, larger structural variantsClinical diagnostic reporting where maximum sensitivity is needed
30×~90–100 GbRare-disease diagnosis (trio/duo/singleton), cancer predisposition, discovery-grade SNV, indel, CNV and SV detectionLow-level mosaicism and somatic tumour variants, which need higher depth

Data volumes are approximate sequencing output for a ~3.1 Gb human genome. Even lower-depth "low-pass" sequencing (well below 1×) is used clinically for aneuploidy and large CNVs; 10× gives much finer CNV resolution plus usable SNV data.

From first principles to expert-level analysis

New here? Start with Foundations. Planning a study or reviewing results? Jump to Practitioner or Expert.

Start here if you are new to this service — six ideas that explain what it is and why it matters.

LEVEL 1

What is whole genome resequencing?

Sequencing an individual's genome and comparing it with the human reference (GRCh38). Reads are aligned to the reference and the differences — variants — are called.

LEVEL 1

What does "coverage" mean?

10×, 20× or 30× means each base is read, on average, 10, 20 or 30 times. More depth gives more confident variant calls — at higher cost.

LEVEL 1

What can 10× WGS do?

Profile copy number across the whole genome and genotype common variants economically in large cohorts. It misses a share of heterozygous variants, so it is not used for diagnosis.

LEVEL 1

Why is 30× the standard?

At 30× the large majority of the genome is covered well enough for confident SNV and indel calling — the depth used by major rare-disease and population programmes worldwide.

LEVEL 1

Why genome instead of exome?

One test reads coding and non-coding DNA with even coverage, and detects CNVs and structural variants that exome and gene panels often miss.

LEVEL 1

What sample do I provide?

EDTA blood, saliva or extracted DNA. Trios need samples from the child and both parents. See the sample table below.

For scientists planning a project or reading a report: how each step works and how it can mislead.

LEVEL 2

Tier selection

CNV and cohort genotyping at 10×; population content at 20×; variant-level diagnosis at 30×. We agree the tier and its detection limits before sequencing.

LEVEL 2

Library and sequencing

PCR-free libraries avoid amplification bias in GC-rich regions and reduce duplicates; 2×150 bp sequencing on NovaSeq 6000/X with indexed pooling.

LEVEL 2

Alignment and variant calling

BWA-MEM2 to GRCh38; SNVs/indels with GATK HaplotypeCaller (joint genotyping for cohorts) or DeepVariant; VQSR or hard filters depending on cohort size.

LEVEL 2

CNV, SV and repeats

Copy number from read depth; structural variants from split-read and discordant-pair evidence. Repeat-expansion screening (ExpansionHunter-class) is part of the Advanced Analysis Package.

LEVEL 2

Annotation and classification

VEP annotation with gene, consequence and population frequency (gnomAD, IndiGenomes); ACMG/AMP classification for clinical-tier projects.

LEVEL 2

Sample and cohort QC

Contamination (VerifyBamID-class), sex check, relatedness and duplicate detection, ancestry inference and batch monitoring — before any variant is interpreted.

For study design: the decisions that determine whether the data answers your question.

LEVEL 3

Detection limits, stated plainly

10× is not used for SNV-level diagnosis; small-CNV and SV sensitivity rise with depth. Every report states the limits of the tier you ordered.

LEVEL 3

Trio design for rare disease

Trio WGS at 30× with de novo calling gives the highest diagnostic yield for developmental delay and congenital anomalies; consanguineous pedigrees add homozygosity-guided recessive analysis.

LEVEL 3

Difficult genes and paralogs

Short reads struggle in segmental duplications and pseudogene-affected loci (SMN1/2, GBA1, CYP21A2, HBA1/2, PMS2) and TTN's triplicated exons. Dedicated callers in our Advanced Analysis Package help (e.g. SMN copy number); long-read follow-up resolves the rest.

LEVEL 3

Germline vs tumour sequencing

Germline predisposition runs at 30×. Somatic tumour–normal designs need higher tumour depth and purity-aware analysis, scoped as a separate programme.

LEVEL 3

PRS in Indian cohorts

Polygenic scores need large training cohorts and out-of-sample validation. Indian populations are under-represented in published PRS weights, so we state transferability caveats explicitly.

LEVEL 3

Data management

A 30× genome is ~90–100 Gb of sequence (roughly 60–100 GB of compressed files). We deliver by secure transfer and support repository submission (IBDC, EGA, dbGaP formats).

Low-pass WGS
very shallow sequencing (typically below 1×) used for aneuploidy and large CNVs.
VQSR
variant quality score recalibration; GATK's cohort-scale filtering method.
De novo variant
present in the child but absent from both parents; a key rare-disease signal.
Homozygosity mapping
finding long homozygous regions to prioritise recessive variants in consanguineous families.
PRS
polygenic risk score; a weighted sum of many risk alleles.
ACMG SF
ACMG secondary findings gene list (v3.3, 2025; 84 genes).

WGS, exome or microarray — what each detects

In a meta-analysis of 37 studies and over 20,000 children with suspected genetic disease, diagnostic yield was 41% for WGS, 36% for exome and 10% for chromosomal microarray (Clark et al., 2018).

Capability30× WGSExome (WES)Chromosomal microarray
Coding SNVs and indelsYes, with even coverageYes; coverage varies by captureNo
Non-coding, deep-intronic, regulatoryYesLargely noNo
CNVsGenome-wide, including small CNVsLimited, exon-levelYes, larger CNVs
Structural variants and breakpointsYes (balanced rearrangements partly)NoUnbalanced only
Repeat expansionsScreening for many known loci (Advanced package)NoNo
Mitochondrial genomeYes (Advanced package)LimitedNo

Prefer an exome? See Whole Exome Sequencing and Clinical Exome Sequencing, or ask us to compare designs for your cohort.

From sample to report

Every step is versioned and logged, so your analysis can be reproduced and defended.

Figure 1 Short-read WGS workflow. schematic
Sample intake& DNA QC PCR-free library NovaSeq 6000 / X2×150 bp Read QC & BWA-MEM2alignment (GRCh38) Sample QC: depth,contamination, sex SNV/indel callingGATK / DeepVariant CNV · SV calling+ advanced modules Annotation, ACMG& report
Figure 1 | Short-read WGS workflow. Variant-calling and annotation modules depend on the tier and disease area. (Illustrative schematic.)

What to send, what you receive

Typical requirements for PCR-free libraries. Lower-input or difficult samples can often be processed with a PCR-based library — ask us first.

Sample typeRecommended amountQuality / handling
Genomic DNA≥1 µg at ≥20 ng/µLA260/280 1.8–2.0, A260/230 ≥1.8; intact high-molecular-weight DNA, no visible degradation
Whole blood2–4 mL in EDTA tubesShip at 2–8 °C within 3 days, or frozen
SalivaOne collection kit per sampleStabilised saliva kit; ship at room temperature
Fresh-frozen tissue≥25 mgShip on dry ice; FFPE is discussed case by case

Deliverables

  • FASTQ files and a sequencing QC report (yield, Q30, depth, % genome ≥10×/≥20×, duplication, insert size)
  • BAM or CRAM alignments to GRCh38
  • VCFs for SNVs/indels, CNVs and SVs (tier-dependent), plus annotated variant tables
  • For clinical-tier projects: prioritised, ACMG/AMP-classified variants for review by the requesting clinician
  • Analysis report with methods, software versions and tier detection limits

Samples are tracked from receipt; data is handled confidentially and delivered by secure transfer. Clinical samples need a signed requisition and consent, including the choice on secondary findings.

Built for the questions you are asking

The platforms, pipelines and standards behind this service.

Illumina NovaSeq 6000 / X

Production-scale 2×150 bp sequencing — the throughput backbone for single genomes and cohort-scale WGS.

Three-tier coverage design

10×, 20× and 30× — depth matched to the question, with detection limits documented for each tier.

GATK best practices + DeepVariant

BWA-MEM2 alignment, joint genotyping for cohorts, deep-learning variant calling, and versioned, reproducible workflows.

Beyond SNVs

CNVs at every tier and SVs at 20× and 30×. Our Advanced Analysis Package adds repeat-expansion screening, SMN1/2 copy number and mitochondrial variant calling.

Consanguinity-aware analysis

Homozygosity mapping, trio de novo detection and recessive prioritisation, with Indian population frequencies in every filter.

ACMG SF v3.3 secondary findings

Optional reporting of actionable findings from the 84-gene ACMG SF v3.3 list, with explicit consent and kept separate from primary results.

Need what short reads cannot see? Our long-read 4 Power Biomarkers test (WGS HiFi with OmniIntegrate AI/ML analysis) and WGS – ONT resolve repeats, paralogs, phasing and methylation.

Depth and detection in pictures

How coverage tier relates to what can be detected. Both figures are illustrative, not client results or benchmark measurements.

10×20×30×Aneuploidy & large CNVs (>1 Mb)Smaller CNVs (tens of kb)Common SNVs (cohort genotyping)Rare heterozygous SNVsSmall indelsStructural variants (>50 bp)Repeat-expansion screening (advanced)Clinical diagnostic reportingRecommendedReduced sensitivityNot suited
Figure 2 | Variant classes suited to each coverage tier. 10× is suited to genome-wide copy number and cohort genotyping; 20× adds population-grade SNV calling and larger SVs; 30× supports discovery-grade SNV, indel, CNV and SV analysis and clinical reporting. (Illustrative summary.)
10×20×30×010203040500%25%50%75%100%SNVsSmall indelsStructural variantsMean sequencing depth (×)Detection sensitivity (schematic)
Figure 3 | Detection sensitivity rises with depth. SNV sensitivity saturates first, indels follow, and structural-variant detection keeps improving with depth — one reason 30× is the standard for discovery and diagnosis. (Schematic curves, not benchmark data.)

What this service does and does not cover

Scope note. Short-read WGS detects variants within the sensitivity limits of each depth: 10× supports copy-number profiling and cohort genotyping; 20× adds population-grade SNV calling and larger structural variants; 30× supports comprehensive SNV/indel discovery and clinical-tier analysis. Short reads have known blind spots — segmental duplications and pseudogene-affected genes (SMN1/2, GBA1, CYP21A2, HBA1/2, PMS2), long tandem repeats, and complex rearrangements. Deep-intronic variants are sequenced but often hard to interpret without RNA evidence. We flag these per gene and can follow up with long-read sequencing. PRS results are population-dependent and need validation. Clinical reporting pathways are agreed at intake with the requesting clinician. Turnaround times and pricing are defined per project.

Service highlights

What you can expect from our team in Hyderabad.

Three tiers, one pipeline family

10×, 20× and 30× on NovaSeq 6000/X with consistent, versioned analysis workflows.

Disease-area expertise

Rare disease, cardiovascular, cancer predisposition, metabolic and NCD cohort programmes.

Built for Indian genomes

Homozygosity-aware analysis and Indian population frequencies for consanguineous and endogamous families.

Honest detection limits

Tier and gene limitations stated in every report, with long-read follow-up available in-house.

Cohort-scale throughput

NovaSeq X capacity for population programmes, with ancestry, relatedness and PRS analyses.

Clinical-grade options

ACMG/AMP classification and ACMG SF v3.3 secondary findings for clinical-tier projects.

Frequently asked, in plain language

From the basics to the finer points of design and interpretation.

basicWhich coverage tier do I need?
Copy-number profiling or cohort genotyping across many samples: 10×. Population programmes: 20×. Variant-level diagnosis or discovery: 30×. We run the detection-limit calculation with you before samples are committed.
basicWhat sample do you need?
EDTA blood, saliva or extracted DNA (ideally ≥1 µg of intact DNA for PCR-free libraries). Trios need the child and both parents for de novo analysis.
basicWhat do I get?
FASTQ, BAM/CRAM alignments, VCFs (SNVs/indels and CNVs, plus SVs at 20×/30×), annotated variant tables, and a written report with methods and tier detection limits.
basicHow much data does one genome produce?
About 30–35 Gb of sequence at 10×, 60–70 Gb at 20× and 90–100 Gb at 30×. CRAM files reduce alignment storage several-fold.
intermediateIs 10× WGS useful for diagnosis?
Not for SNV or indel diagnosis — at 10× a share of heterozygous variants is missed. It is well suited to genome-wide copy number and cohort genotyping. Diagnosis should use 30×.
intermediateCan you analyse consanguineous families?
Yes — homozygosity mapping and recessive-variant prioritisation within shared ancestral regions are standard in our rare-disease workflow.
intermediateAre secondary findings reported?
Only if chosen, per the ACMG SF v3.3 list (2025), with explicit consent and kept separate from primary results.
advancedWhat are the short-read blind spots?
Segmental duplications and pseudogene-affected genes (SMN1/2, GBA1, CYP21A2, HBA1/2, PMS2), TTN's triplicated exons, long tandem repeats and complex rearrangements. Deep-intronic variants are sequenced but often need RNA evidence to interpret. We flag these per gene and offer long-read follow-up in-house.
advancedCan short-read WGS detect repeat expansions, SMA and mitochondrial variants?
Yes, through our optional Advanced Analysis Package at 30×: many known repeat-expansion loci are screened, SMN1/SMN2 copy number is estimated with dedicated callers, and mitochondrial variants are called. Positive or borderline results are confirmed with an orthogonal or long-read method.
advancedCan you build polygenic risk scores from my cohort?
Where cohort size and replication data support it — with explicit transferability caveats, since published PRS weights under-represent Indian populations.
advancedCan tumour–normal somatic designs be added?
Yes — germline predisposition runs at 30×; somatic programmes need higher tumour depth and purity-aware analysis, scoped as a separate design.
advancedHow is cohort quality controlled?
Per-sample depth and contamination metrics, sex checks, relatedness and duplicate detection, ancestry inference, and batch-effect monitoring across the cohort.

Key literature & resources

Selected sources behind the methods and figures on this page.

  1. Lee K, et al. ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the ACMG. Genetics in Medicine. 2025;27(8):101454.
  2. Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and AMP. Genetics in Medicine. 2015;17(5):405–424.
  3. DePristo MA, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genetics. 2011;43(5):491–498.
  4. Poplin R, et al. A universal SNP and small-indel variant caller using deep neural networks (DeepVariant). Nature Biotechnology. 2018;36(10):983–987.
  5. Vasimuddin M, et al. Efficient architecture-aware acceleration of BWA-MEM for multicore systems (BWA-MEM2). IEEE IPDPS. 2019:314–324.
  6. Chen X, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32(8):1220–1222.
  7. Dolzhenko E, et al. ExpansionHunter: a sequence-graph-based tool to analyze variation in short tandem repeat regions. Bioinformatics. 2019;35(22):4754–4756.
  8. Clark MM, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. npj Genomic Medicine. 2018;3:16.
  9. Karczewski KJ, et al. The mutational constraint spectrum quantified from variation in 141,456 humans (gnomAD). Nature. 2020;581(7809):434–443.
  10. Jain A, et al. IndiGenomes: a comprehensive resource of genetic variants from over 1000 Indian genomes. Nucleic Acids Research. 2021;49(D1):D1225–D1232.
  11. Martin AR, et al. Human demographic history impacts genetic risk prediction across diverse populations. American Journal of Human Genetics. 2017;100(4):635–649.
  12. Qian Y, et al. Validation and depth evaluation of low-pass genome sequencing in prenatal diagnosis using 387 amniotic fluid samples. Journal of Medical Genetics. 2023;60(10):933–938.
  13. Kariyaiah S, et al. Low pass whole genome sequencing — a cost-effective technique for the identification of aneuploidies and copy number variations: a study of 1372 clinical samples in an Indian cohort. medRxiv. 2025. doi:10.1101/2025.05.18.25327314